SecBot SecBot
8-K ·Filed Nov 5, 2026

COLL

COLLEGIUM PHARMACEUTICAL, INC
NEUTRAL
Impact 5/10
Horizonweeks Processed11d 19h ago SEC0001628280-26-070585
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The ADHD portfolio is accelerating (JORNAY PM +24%, AZSTARYS ramping) but the pain portfolio decline is accelerating too (Nucynta -44%). With guidance reaffirmed, the key swing factor is whether AZSTARYS can sustain its growth trajectory into Q4 and whether the pain portfolio erosion stabilizes. Monitor Q4 revenue mix and any guidance update at upcoming investor conferences.

DirectionNeutral
Confidencehigh
Horizonweeks

Nucynta ER

● Neutral Named in this 8-K
Impact
Phase
Approved
Time to market
Already on the market — approved since 2008 (IR) and 2011 (ER)
Next catalyst
None dated

What to watchNucynta ER itself is not a catalyst for COLL. The stock's next binary event is Q3 2026 earnings on November 5, 2026, where the market will focus on guidance for the integrated portfolio including the AZSTARYS acquisition. Investors should watch for Nucynta's ongoing revenue erosion from generic tapentadol, and whether Collegium's ADHD pivot can offset pain-portfolio declines to justify the analyst consensus ~$49 target.

Price Chart

Loading chart...

Executive Summary

Collegium reported Q3 2026 net revenue of $216.3M (+3% YoY) and adjusted EPS of $1.96, beating the $1.86 consensus. ADHD portfolio strength (JORNAY PM +24% YoY, AZSTARYS $26.5M in first full quarter) was offset by a 9% decline in adjusted EBITDA to $121.6M and an 18% drop in pain portfolio revenue. Full-year 2026 guidance was reaffirmed.

Key Financial Metrics

EPS (Adj.)
$1.96
est $1.86 · +5.4% · GAAP: $0.60
Revenue
$216.3M
est $216.0M · +0.2% · +3.3% YoY
Rating
beat
Guidance
$825M-$855M
maintained
Gross Margin
57.97%

Key Facts

  • Q3 2026 product revenue $216.3M, up 3% YoY from $209.4M
  • Adjusted EPS $1.96 vs consensus $1.86, a beat of 5.4%
  • GAAP diluted EPS $0.60 vs $0.84 YoY
  • Adjusted EBITDA $121.6M, down 9% from $133.0M YoY
  • JORNAY PM revenue $51.9M, up 24% YoY; AZSTARYS $26.5M in first full quarter
  • Pain portfolio revenue $138.0M, down 18% YoY; Nucynta franchise down 44%
  • Full-year 2026 guidance reaffirmed: product revenue $825-$855M, adjusted EBITDA $445-$470M
  • Generated $86.5M cash from operations; ended quarter with $144.8M cash and marketable securities
  • Announced $50M accelerated share repurchase program in Q3 2026

Financial Impact

Revenue $216.3M (+3% YoY), adjusted EPS $1.96 beat consensus $1.86 by $0.10

revenueepsadjusted ebitdacash flow

Segment Breakdown

SegmentRevenueGrowth
JORNAY PM$51.9M+24.0%
AZSTARYS$26.5MNot reported
Pain Portfolio$138.0M-18.0%
Belbuca$57.7M-1.0%
Xtampza ER$45.8M-9.0%
Nucynta Franchise$30.8M-44.0%

Risk Factors

  • Pain portfolio revenue declining 18% YoY, with Nucynta franchise down 44%
  • Adjusted EBITDA down 9% YoY despite revenue growth, reflecting higher operating expenses
  • GAAP net income $21.8M vs $31.5M YoY, down 31%
  • High debt load ($842.5M term notes, $239.0M convertible notes) relative to $773M market cap

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-070585
Document: collq32026earningspresen.htm0001628280-26-070585
Document: coll-20261105.htm0001628280-26-070585
Document: 0001628280-26-070585-index-headers.html0001628280-26-070585
Document: 0001628280-26-070585-index.html0001628280-26-070585
Document: 0001628280-26-070585.txt0001628280-26-070585
8-K Data (Synthetic)0001628280-26-070585

Track record

24 reports on COLL

Performance horizon

1 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +0.28% at T+1 after the Aug 13, 2026 report. 1 of 6 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $25.68 Now $25.43 −0.97% settles Nov 17
  2. Nov 10, 20266d ago SC 13G/A Bearish 4/10 Entry $24.47 to $24.81 Now $25.43 −3.92% ▼ −1.39% −0.07% vs SPY
  3. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $24.47 to $24.81 Now $25.43 +3.92% ▲ +1.39% +0.07% vs SPY
  4. Nov 9, 20267d ago Institutional Cluster Bearish 4/10 Entry $24.47 to $24.81 Now $25.43 −3.92% ▼ −1.39% −0.07% vs SPY
  5. Nov 5, 202611d ago 8-K Neutral 5/10 Viewing No price data
  6. Nov 5, 202611d ago Press Release Neutral 5/10 Entry $25.16 to $24.21 Now $25.43 +1.07% ▼ −3.78% −4.09% vs SPY
  7. Oct 30, 202617d ago SC 13G/A Neutral 3/10 Entry $23.80 to $23.68 Now $25.43 +6.85% ▼ −0.50% −0.03% vs SPY
  8. Oct 29, 202618d ago SC 13G/A Neutral 3/10 Entry $24.03 to $23.80 Now $25.43 +5.83% ▼ −0.96% +0.82% vs SPY
  9. Oct 29, 202618d ago Press Release Neutral 2/10 Entry $24.03 to $23.80 Now $25.43 +5.83% ▼ −0.96% +0.82% vs SPY
  10. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $23.50 to $22.96 Now $25.43 +8.21% ▼ −2.30% −1.78% vs SPY
Showing 10 of 24

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026